May 2024 — Monthly Briefing¶
1. What was read¶
784 research articles from 32 of the 33 journals on the roster.
A further 102 records (12% of the 886 this month's harvest returned) carry no abstract and are not research: news, correspondence, editor highlights and obituaries. PubMed types them Journal Article and nothing else, so the publication-type filter cannot see them — across the whole index they are 22.7% of it and 35% of general, and 3,801 of them are JAMA. Every count below is over the full harvest and is inflated by this; the figure above is not.
| General | Cancer | Immune | Bioinfo | Sysbio |
|---|---|---|---|---|
| 396 | 141 | 91 | 235 | 23 |
Largest contributors: Nature 121, Science 94, Nucleic Acids Res 84, Bioinformatics 57, JAMA 38, J Clin Oncol 33.
2. Net change on the thread curve¶
| Thread | This month | Cumulative | Status |
|---|---|---|---|
agentic-ai |
— | +4 / −0 | too-early |
cell-therapy |
+5 / −3 | +104 / −35 | forming |
ctdna-mrd |
+2 | +34 / −15 | forming |
foundation-models |
+3 / −1 | +44 / −30 | splitting |
immunotherapy-resistance |
+7 / −1 | +112 / −37 | forming |
interception |
+1 / −2 | +67 / −11 | forming |
method-credibility |
+2 / −17 | +5 / −206 | crisis |
neoantigen-vaccines |
+4 | +49 / −19 | forming |
neuro-immune-microbiome-axis |
+4 / −2 | +80 / −10 | forming |
next-gen-checkpoints |
+3 / −1 | +34 / −23 | splitting |
single-cell-3d-genome |
+3 / −4 | +32 / −13 | forming |
suppressive-population-inversion |
+1 / −4 | +26 / −36 | contested |
Status is derived by rule, not asserted. Fewer than 5 cards → too-early; then refutes ≥ 2×supports → crisis; refutes > supports → contested; supports ≥ 2×refutes → forming; else splitting.
3. The evidence that moved it¶
The most direct refutation on the microbiome thread is from May 2024, and it is narrower than its title. 38689063 (Nat Med) profiles the faecal microbiota of 589 patients across colorectal cancer stages and compares against up to 15 published studies totalling 4,439 subjects, using quantitative profiling — absolute rather than relative abundance — with transit time, faecal calprotectin and body mass index as covariates. Those three covariates explain more variance than the diagnostic groups do, and under them the association between Fusobacterium nucleatum and CRC stage dissolves. Six other taxa, including Parvimonas micra and Peptostreptococcus anaerobius, survive the same control and are named as targets worth keeping. So this is a confounding result and not a null: it removes the field's most cited microbial target and leaves the microbial account standing. It also finds that controls who meet the criteria for colonoscopy but have no lesion are enriched for a dysbiotic enterotype, which is a problem for every case-control design in the area.
Corrected 2026-08-27
Two sentences have come out. The paper was read as challenging predicted microbial targets wholesale; six of them survive its own confounder control, and the corrected description is above. And it was said to predate "the thread's first recorded card by sixteen months" — the thread now opens in 2023-01, so the arithmetic has been wrong since the backfill. A boast about a gap measured from the edge of what has been read has not once survived the edge moving.
A myeloid target is removed and the outcome improves; another is removed and
the sign turns out to have been backwards. 38758808 (Sci Immunol):
deleting TREM2 — a receptor this corpus already cards as nominated for
suppression on tumour macrophages (37081148, May 2023) — drives a
proinflammatory programme in intestinal macrophages, expands Ruminococcus
gnavus in the gut, and enhances anti-PD-1 tumour elimination, with TNF-producing
CD4 T cells expanding and migrating to the tumour bed. Gavaging wild-type mice
with R. gnavus reproduces the effect without touching TREM2 at all, which puts
the mechanism in the intestine rather than in the tumour. That is the
suppressive-population-inversion claim confirmed: remove the population, the
outcome improves. 38684922 (Nat Immunol) is the harder case and the
one filed as a refutation — sepsis-trained macrophages promote antitumoural
tissue-resident T cells, so a myeloid state assumed suppressive is protective and
depleting it would cost. The thread is running on both of its sides in May 2024.
Corrected 2026-08-27
The TREM2 paper was carded refutes, and the old claim's closing sentence
was "Removing a population improves the outcome" — which is this thread's
claim word for word, filed as a refutation of it. On this thread refutes is
reserved for inversions, where a population assumed suppressive turns out
protective; deletion improving the outcome is the supporting case. The stance
is now supports.
And the same month supplies its mirror image. 38664585 (Nat Immunol): a dietary commensal microbe enhances antitumour immunity by activating tumour macrophages to sequester iron. The same cell type, in the same journal, in the same month, as an asset rather than a liability. That is the thread's actual shape: not that suppressive populations are secretly good, but that the sign is context-dependent and the field keeps assigning it globally.
4. Refutations¶
(a) Landing on a tracked thread¶
The sepsis-macrophage paper above is the month's refutation on
suppressive-population-inversion and is filed there rather than here to avoid
double-counting; the TREM2 paper beside it supports that thread and is not a
refutation of anything.
38227896 (Cancer Discov) refutes immunotherapy-resistance, and it
does so by being an excellent paper about the wrong compartment. Cancer cells
adaptively induce TREX1 through autocrine interferon and downstream STAT1, and
TREX1 degrades cytosolic DNA and so caps the cell's own STING-interferon
signalling before it can amplify. Inactivating TREX1 in the cancer cell
recruits T and NK cells, sensitises to NK-derived interferon-γ, and cooperates
with PD-1 blockade across mouse models. The thread's claim is that resistance is
being explained outside the tumour cell; the abstract locates the brake inside
it, five times over. The corpus already cards this exact shape as a refutation
(37553183, August 2023, tumour-cell-intrinsic and not host STING).
Corrected 2026-08-27
This entry read "38227896 (Cancer Discov) is the supporting side of
immunotherapy-resistance". The stance was set by the title's upbeat verb —
"unleashes … promotes antitumour immunity" — rather than by where the paper
puts the machinery, and it is now refutes.
(b) Method credibility¶
The microbiome-confounders paper is the month's methodological result as well as its biological one, which is the combination this corpus values most highly: the reading and the finding are the same object. It does say that one particular target is wrong, but the load-bearing claim is the general one: relative-abundance profiling without covariate control cannot separate a microbial signal from transit time, inflammation and body mass, and those are the variables that explain most of the variance the field has been reading as disease.
5. Open items¶
Nothing carried forward.
6. Meetings¶
No abstract book published this month. The abstract layer runs 2023-02 to 2026-08 and is seasonal by nature — meetings are annual, so most months are empty here and that is the expected shape, not a gap in the harvest.
7. Regulatory¶
| Event | Count |
|---|---|
| trial-first-posted | 523 (of which 464 genuinely oncology) |
| ema-authorisation | 9 |
| fda-approval | 4 |
4 FDA actions — dated from each notice's own prose, not the table's posting date, which disagrees on 7 of 190 rows and once by enough to move an approval into the wrong month:
- 2024-05-15 — FDA grants accelerated approval to lisocabtagene maraleucel for follicular lymphoma
- 2024-05-16 — FDA grants accelerated approval to tarlatamab-dlle for extensive stage small cell lung cancer
- 2024-05-29 — FDA grants accelerated approval to selpercatinib for pediatric patients two years and older with RET-altered metastatic thyroid cancer or solid tumors
- 2024-05-30 — FDA approves lisocabtagene maraleucel for relapsed or refractory mantle cell lymphoma
2 EMA oncology authorisations:
- 2024-05-17 — Wyost
- 2024-05-29 — Agilus
8. Trade press¶
48 on-topic of 323 items across 3 feeds (n-stat 306, n-aacr-blog 12, n-acir 5). Headlines are selected by subject keyword, not recency — most of what these feeds carry is health policy and industry finance the corpus does not read.
- 2024-05-31 — New Grant Will Fund Fanconi Anemia-related Cancer Research —
n-aacr-blog - 2024-05-31 — STAT+: FDA approves Moderna’s RSV vaccine, its second licensed product —
n-stat - 2024-05-31 — STAT+: For one rare type of lung cancer, Pfizer pill reduces progression by 81% —
n-stat - 2024-05-30 — STAT+: Ultragenyx gene therapy for rare liver ailment succeeds in late-stage trial —
n-stat - 2024-05-29 — TIL Therapy: A New Melanoma Treatment 30 Years in the Making —
n-aacr-blog - 2024-05-29 — STAT+: NIH-funded clinical trials often miss racial, gender diversity enrollment goals, report finds —
n-stat - 2024-05-28 — ASCO 2024: the latest in cancer research —
n-stat - 2024-05-28 — STAT+: Merus drug, with immunotherapy, boosts tumor response in patients with head and neck cancer —
n-stat - 2024-05-27 — STAT+: ASCO preview: a promising solid tumor CAR-T, an AI patient navigator, and improving palliative care —
n-stat - 2024-05-24 — Editors’ Picks, May 2024: Machine Learning in Cancer Research, the Cost of Smoking, and More —
n-aacr-blog - 2024-05-24 — Opinion: STAT+: Unmasking the ‘centricity’ illusion in clinical trials —
n-stat - 2024-05-23 — STAT+: FDA advisers endorse Guardant Health’s colon cancer screening test —
n-stat - … and 36 more on-topic items.